Inhibikase Therapeutics GAAP EPS of -$0.65 misses by $0.17 [Seeking Alpha]
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
Inhibikase Therapeutics, Inc. (NYSE: IKT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $8.00 price target on the stock.
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension [Yahoo! Finance]
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension